Focus on lomefloxacin: effectiveness and safety

The results of clinical studies on the use of lomefloxacin for various diseases are presented.
The purpose of this study was to analyze the effectiveness and safety of lomefloxacin based on the results of clinical studies published in the scientific literature. Extensive clinical experience with the use of fluoroquinolones in millions of patients indicates their high effectiveness in treating infections of various origins and localities. Lomefloxacin, a difluorinate representative of the fluoroquinolone group, is a bactericidal agent with a wide spectrum of antimicrobial activity against gram-negative and gram-positive microorganisms. The most important property of lomefloxacin is its high bioavailability — more than 98 % when administered orally.
The effectiveness of oral lomefloxacin against respiratory tract, urinary tract, obstetric, and gynecological infections, joint infections, skin infections, and mouth, ears, nose, throat, and eyes infections has been studied. Moreover, lomefloxacin has been used as an otic solution to treat otitis media and in the form of an ophthalmic solution to treat eye infections.
In studies conducted in Western countries, 72 to 94 % of patients with respiratory tract infections treated with lomefloxacin (400 mg once daily) experienced improvement in clinical symptoms: the causative bacteria were eliminated in 80 to 90 % of cases. Lomefloxacin was well tolerated, and most adverse effects were mild to moderate and reversible. The most common adverse events were gastrointestinal symptoms (nausea, diarrhea, pain/discomfort). In addition, headache, dizziness, transient insomnia, skin hypersensitivity reactions, including photosensitivity, were reported in fewer patients.
Based on extensive clinical experience with the use of lomefloxacin, it can be argued that the drug has established itself as a drug with proven effectiveness and a known safety profile.

1. Wadworth AN, Goa KL. Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1991 Dec;42(6):1018-60. doi: 10.2165/00003495-199142060-00009. Erratum in: Drugs 1992 Jul;44(1):8.

2. Kemper P, Köhler D. A double-blind study of two dosage regimens of lomefloxacin in bacteriologically proven exacerbations of chronic bronchitis of gram-negative etiology. Am J Med. 1992 Apr 6;92(4A):98S-102S. doi: 10.1016/0002-9343(92)90318-6.

3. Gotfried MH, Ellison WT. Safety and efficacy of lomefloxacin versus cefaclor in the treatment of acute exacerbations of chronic bronchitis. Am J Med. 1992 Apr 6;92(4A):108S-113S. doi: 10.1016/0002-9343 (92)90320-b.

4. www.accessdata.fda.gov. Maxaquin® lomefloxacin hydrochloride tablets. 2005. https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/20013s015lbl.pdf

5. Kawamura N, Nishizawa K, Kawashima T, et al. [Clinical effect of NY- 198 (lomefloxacin) for sexually transmitted disease--bacteriological effect of U. urealyticum]. Kansenshogaku Zasshi. 1990 Jan;64(1):1-11. Japanese. doi: 10.11150/kansenshogakuzasshi1970.64.1.

6. Kumamoto Y, Henmi I, Tsunekawa T, et al. [Epidemiological and therapeutic study on gonorrheal infection--study on NY-198 (lomefloxacin) single administration therapy. Sapporo Clinical Research Group for STD]. Hinyokika Kiyo. 1990 Aug;36(8):969-77. Japanese.

7. Kumamoto Y, Miyagishi T, Hirose T, et al. [Epidemiological and therapeutic study on urethritis of male and cervicitis from viewpoint of STD--a study using NY-198. Sapporo Clinical Research Group for STD]. Hinyokika Kiyo. 1990 Aug;36(8):979-87. Japanese.

8. Morihana T, Kaneko A. Clinical study of NY-198 in oral infections. Chemotherapy. 1988;36(Suppl. 2, Pt 2):1371-1377. doi: 10.11250/chemotherapy1953.36. Supplement2-Clinical_1371.

9. Aoki T, Saito M, Shimizu N, et al. Clinical study of NY-198 in infectious enteritis. Chemotherapy. 1988;36 (Suppl. 2, Pt 2):792-802. doi: 10.11250/chemotherapy1953.36.Supplement2-Clinical_792.

10. Martín-Luengo F, Fontana L, Rico JL, et al. Prophylaxis in transurethral surgery: oral lomefloxacin versus intravenous cefuroxime. Methods Find Exp Clin Pharmacol. 1993 Jan-Feb;15(1):57-9.

11. Neringer R, Forsgren A, Hansson C, Ode B. Lomefloxacin versus norfloxacin in the treatment of uncomplicated urinary tract infections: three-day versus seven-day treatment. The South Swedish Lolex Study Group. Scand J Infect Dis. 1992;24(6):773-80. doi: 10.3109/00365549209062463.

12. Iravani A. Efficacy of lomefloxacin as compared to norfloxacin in the treatment of uncomplicated urinary tract infections in adults. Am J Med. 1992 Apr 6;92(4A):75S-81S. doi: 10.1016/0002-9343(92)90314-2.

13. Grassi C, Albera C, Pozzi E. Lomefloxacin versus amoxicillin in the treatment of acute exacerbations of chronic bronchitis: an Italian multicenter study. Am J Med. 1992 Apr 6;92(4A):103S-107S. doi: 10.1016/0002-9343(92)90319-7.

14. Klimberg IW, Childs SJ, Madore RJ, Klimberg SR. A multicenter comparison of oral lomefloxacin versus parenteral cefotaxime as prophylactic agents in transurethral surgery. Am J Med. 1992 Apr 6;92(4A):121S-125S. doi: 10.1016/0002-9343(92)90323-4.

15. Nicolle LE, Louie TJ, Dubois J, et al. Treatment of complicated urinary tract infections with lomefloxacin compared with that with trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother. 1994 Jun;38(6):1368-73. doi: 10.1128/AAC.38.6.1368.

16. Cox CE. A comparison of the safety and efficacy of lomefloxacin and ciprofloxacin in the treatment of complicated or recurrent urinary tract infections. Am J Med. 1992 Apr 6;92(4A):82S-86S. doi: 10.1016/0002-9343(92)90315-3.

17. Westenfelder M, Zeman W. A multicenter study of lomefloxacin versus ciprofloxacin in the treatment of complicated urinary tract infections. Int J Antimicrob Agents. 1992 Dec;2(1):29-32. doi: 10.1016/0924-8579(92)90024-l.

18. Ohmori H, Kumon H, Suzuki K, Kamidono S, Arakawa S, Ishigami J, Tanaka H, Amano M, Fujita Y, Kanemasa Y, et al. [A comparative study on lomefloxacin and norfloxacin in the treatment of acute uncomplicated cystitis]. Jpn J Antibiot. 1989 Apr;42(4):1025-50. Japanese.